(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 June 2004 (10.06.2004)

PCT

(10) International Publication Number
WO 2004/047716 A3

(51) International Patent Classification[7]: C07C 49/217, A61K 31/12

(21) International Application Number: PCT/BR2003/000177

(22) International Filing Date: 28 November 2003 (28.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PI 0207141-0 28 November 2002 (28.11.2002) BR

(71) Applicant *(for all designated States except US)*: **FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO** [BR/BR]; 1500, Pio XI Street, Alto da Lapa Ward, 05468-901 São Paulo (BR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SUÁREZ, José, Agustin Quincoces** [/BR]; 427, Barão de Tatuí Street Apt.41, Santa Cecília Ward, 01226-030 São Paulo - SP (BR). **PESEKE, Klaus** [/DE]; Haselhof 1, Lichtenhagen, 18107 Elmenhors Lictenhagen (DE). **KORDIAN, Marcus** [/DE]; Zorenappelweg 12, 18055 Rostock (DB). **CARVALHO, João, Ernesto** [/BR]; 140, Emílio Ribas Street Apt. 104, Cambuí Ward, 13000-025 Campinas - SP (BR). **KOHN, Luciana, Konecny** [/BR]; 12, Cristovam Bonini Street, Jd Proença Ward, 13096-040 Campinas - SP (BR). **ANTÔNIO, Márcia, Aparecida** [/BR]; 13, Victor Zamperlim Street, João Aranha Ward, 13140-000 Paulínia - SP (BR). **BRUNHARI, Heloíza** [/BR]; 537, Sílvio Carbosa Street, Vila São Jorge Ward, 07111-010 Guarulhos - SP (BR).

(74) Agent: **BEERRE ASSESSORIA EMPRESARIAL S/C LTDA**; 3236, Barão de Itapura Avenue, Taquaral Ward, 13073-300 Campinas - SP (BR).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
19 August 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/047716 A3

(54) Title: NEW METHOD FOR THE PREPARATION OF 1,5-BIS(4-HYDROXY-3-METOXY-PHENYL)-PENTA-1,4-DIEN-3-ONE AND DERIVATIVES WITH ANTITUMORAL PROPERTIES

(57) Abstract: This patent of invention reports the method for the preparation of 1,5-bis(4-hydroxy-3-methoxyphenyl)-penta-1,4-dien-3-one and derivatives with antitumoral properties: the sample denominated 37 compound was obtained with high yield and purity with ultrasonic technique presenting cytostatic activity (growth inhibition) in the concentrations evaluated and cytotoxic activity (cellular death) from the concentration of 0,25 mg/mL against nine different types of human cancer cell lines. This compound has a LD50, equals to 8,54 g/Kg. That means this product can be considered itself as practically nontoxic. Doxorubicin, anticarcinogen medicine used as reference in all these tests, is a product extremely toxic (LD50 of 20 mg/Kg) and it does not inhibit the growth of Mama NCI-ADR cell line (the one that expresses the phenotype of resistance against multiple drugs), therefore our product presented a strong cytostatic activity. Other derivatives also presented a strong cytostatic activity, specially the one denominated EHB1 compound.